Qiagen stock holds near 43 dollars after steady analyst view

Published on 09/03/2026 at 06:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock stays near 43 dollars as the latest quarter and a hold-rated consensus frame the shares for investors. The German-quoted diagnostics name also keeps its mid-cap profile in view.

Weißer Reinraum-Korridor mit Glaswänden, klare Linien, klinische Atmosphäre — Qiagen N.V. (NL0012169213) weißer Reinraum-Korridor mit Glaswänden, klaren Linien und klinisch-kühler, sterile Laboratmosphäre, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0012169213) traded around USD 43.23 on August 31, 2026, with a market capitalization of USD 8.926 billion. The latest quarterly snapshot showed USD 0.62 earnings per share on USD 535.04 million revenue, versus USD 0.60 EPS and USD 527.50 million expected.

Quarterly numbers matter

That means EPS beat consensus by USD 0.02 and sales topped estimates by about USD 7.54 million. Revenue was also described as up 0.2 percent year on year, while the share price sat only a little below the USD 43.93 average 12-month target cited in a consensus overview.

Market level and valuation

As of September 2, 2026, a separate market snapshot placed Qiagen stock at about USD 43.23 to USD 43.39, with the stock still moving in a narrow band around that level. For investors, the combination of USD 8.926 billion market value and a hold-rated target view points to a valuation that is not stretching far beyond current trading.

Go deeper

Qiagen stock data and company details

Key market figures and company details for Qiagen at a glance.

Qiagen coverage Investor Relations

Franklin platform in focus

One representative product angle is Franklin, QIAGEN's platform for germline variant analysis and interpretation. The company is presenting it in a 2026 conference context, which keeps the product side tied to current laboratory workflows rather than an evergreen profile.

What the stock shows

Qiagen stock closed the latest snapshot near USD 43.23, and the broader range cited in early September stayed close to that level. The number that matters most now is the gap between the USD 43.23 price point and the USD 43.93 consensus target, which leaves limited room in the current analyst view.